- Home
- LSF vs CELU Comparison
LSF vs CELU Comparison
Compare LSF & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSF
- CELU
- Stock Information
- Founded
- LSF 2015
- CELU 2016
- Country
- LSF United States
- CELU United States
- Employees
- LSF N/A
- CELU N/A
- Industry
- LSF Packaged Foods
- CELU Biotechnology: Pharmaceutical Preparations
- Sector
- LSF Consumer Staples
- CELU Health Care
- Exchange
- LSF Nasdaq
- CELU Nasdaq
- Market Cap
- LSF 62.0M
- CELU 56.9M
- IPO Year
- LSF 2020
- CELU N/A
- Fundamental
- Price
- LSF $4.92
- CELU $1.98
- Analyst Decision
- LSF Strong Buy
- CELU Strong Buy
- Analyst Count
- LSF 2
- CELU 1
- Target Price
- LSF $12.00
- CELU $6.00
- AVG Volume (30 Days)
- LSF 26.0K
- CELU 224.7K
- Earning Date
- LSF 11-05-2025
- CELU 12-05-2025
- Dividend Yield
- LSF N/A
- CELU N/A
- EPS Growth
- LSF N/A
- CELU N/A
- EPS
- LSF N/A
- CELU N/A
- Revenue
- LSF $47,027,546.00
- CELU $44,590,000.00
- Revenue This Year
- LSF $21.88
- CELU N/A
- Revenue Next Year
- LSF $20.86
- CELU $76.00
- P/E Ratio
- LSF N/A
- CELU N/A
- Revenue Growth
- LSF 22.79
- CELU 4.45
- 52 Week Low
- LSF $4.45
- CELU $1.00
- 52 Week High
- LSF $10.90
- CELU $5.22
- Technical
- Relative Strength Index (RSI)
- LSF 29.65
- CELU 39.59
- Support Level
- LSF $5.00
- CELU $1.99
- Resistance Level
- LSF $5.43
- CELU $2.35
- Average True Range (ATR)
- LSF 0.29
- CELU 0.16
- MACD
- LSF -0.07
- CELU 0.03
- Stochastic Oscillator
- LSF 7.62
- CELU 7.90
About LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About CELU Celularity Inc.
Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.